West Pharmaceutical Services, Inc. (WST) Q1 2023 Earnings Call Transcript

SA Transcripts
153.96K Followers

Q1: 2023-04-27 Earnings Summary

EPS of $1.98 beats by $0.31
 | Revenue of $716.60M (-0.47% Y/Y) beats by $19.32M

West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2023 Results Conference Call April 27, 2023 9:00 AM ET

Company Participants

Quintin Lai - IR
Eric Green - CEO
Bernard Birkett - CFO

Conference Call Participants

Larry Solow - CJS Securities
Paul Knight - KeyBanc Capital Markets
Matt Larew - William Blair
Jacob Johnson - Stephens
Derik De Bruin - Bank of America
John Sourbeer - UBS

Quintin Lai

[Call Starts Abruptly] …conference call. We issued our financial results this morning, and the release has been posted in the Investors section on the company's website located at westpharma.com.

This morning, Eric Green and Bernard Birkett will review our financial results, provide an update on our business and present an update on our financial outlook for the full year 2023. There's a slide presentation that accompanies today's call and a copy of that presentation is available on the Investors section of our website.

On Slide 4, our safe harbor statement. Statements made by the management on this call and in the accompanying presentation contain forward-looking statements within the meaning of U.S. federal securities law. These statements are based on our beliefs and assumptions, current expectations, estimates and forecasts. The company's future results are influenced by many factors beyond the control of the company. Actual results could differ materially from past results as well as those expressed or implied in any forward-looking statements made here. Please refer to today's press release as well as any other disclosures made by the company regarding the risks to which it is subject, including our 10-K, 10-Q and 8-K reports.

During today's call, management will make reference to non-GAAP financial measures, including organic sales growth, adjusted operating profit, adjusted operating profit margin and adjusted diluted EPS. Reconciliations and limitations of the non-GAAP financial measures to the most comparable financial results prepared in conformity to

Recommended For You

About WST Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on WST